Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Treon

Showing results (191-200 of 323) with videos related to

Pageof 33
Sort By:
Blood|October 28, 2018
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patientsRomanos Sklavenitis-Pistofidis, Marzia Capelletti, Chia-Jen Liu, et al.
Cancer Research|December 17, 2005
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implicationsYu-Tzu Tai, Xian-Feng Li, Laurence Catley, et al.
Blood|May 27, 2014
Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemiaSteven P Treon, Christina K Tripsas, Kirsten Meid, et al.
Blood Advances|July 17, 2025
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemiaJorge J Castillo, Alberto Guijosa, John N Allan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2015
Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström MacroglobulinemiaIsere Kuiatse, Veerabhadran Baladandayuthapani, Heather Y Lin, et al.
British Journal of Haematology|March 13, 2021
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemiaJoshua N Gustine, Lian Xu, Guang Yang, et al.
Blood Advances|October 21, 2020
Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemiaJorge J Castillo, Edward N Libby, Stephen M Ansell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemiaAldo M Roccaro, Xavier Leleu, Antonio Sacco, et al.
Cancer Epidemiology|November 22, 2011
Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary studyRohit P Ojha, Christina A Hanzis, Zachary R Hunter, et al.
British Journal of Haematology|June 10, 2008
The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemiaAnne-Sophie Moreau, Xiaoying Jia, Christopher J Patterson, et al.
Pageof 33

Showing results (191-200 of 323) with videos related to

Sort By:
Pageof 33
Blood|October 28, 2018
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patientsRomanos Sklavenitis-Pistofidis, Marzia Capelletti, Chia-Jen Liu, et al.
Cancer Research|December 17, 2005
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implicationsYu-Tzu Tai, Xian-Feng Li, Laurence Catley, et al.
Blood|May 27, 2014
Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemiaSteven P Treon, Christina K Tripsas, Kirsten Meid, et al.
Blood Advances|July 17, 2025
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemiaJorge J Castillo, Alberto Guijosa, John N Allan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2015
Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström MacroglobulinemiaIsere Kuiatse, Veerabhadran Baladandayuthapani, Heather Y Lin, et al.
British Journal of Haematology|March 13, 2021
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemiaJoshua N Gustine, Lian Xu, Guang Yang, et al.
Blood Advances|October 21, 2020
Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemiaJorge J Castillo, Edward N Libby, Stephen M Ansell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemiaAldo M Roccaro, Xavier Leleu, Antonio Sacco, et al.
Cancer Epidemiology|November 22, 2011
Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary studyRohit P Ojha, Christina A Hanzis, Zachary R Hunter, et al.
British Journal of Haematology|June 10, 2008
The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemiaAnne-Sophie Moreau, Xiaoying Jia, Christopher J Patterson, et al.
Pageof 33